weight loss response to semaglutide in postmenopausal women Our Chief Medical Officer, Dr. Kathleen Jordan, reviewed a recent PubMed study that affirms that if you notice quite a few extra pounds during your peri/menopausal journey, it’s not you—it’s your New study links combination of

M., Meyer, M., & Trinkley, K

Functional and phenotypic analyses confirm the induction of a pancreatic endocrine fate, including positive dithizone (DTZ) staining indicative of insulin production, as well as the upregulation of key pancreatic markers such as paired box gene 4 (PAX4), neurogenin 3 (NGN3), Isl-1, Some protocols utilized additional strategies like fibrin encapsulation, decellularized amniotic membrane [52] or 3D alginate encapsulation [51] scaffolds to enhance differentiation efficiency and mimic physiological conditions more closely

While perfect adherence leads to higher premium costs due to sustained drug use, even short-term GLP-1 use incurs high pharmacy spend

The FDA recently approved another use for semaglutide, allowing it to help patients battling chronic weight management

Converting everyday observations into clear, actionable patterns is essential for making informed treatment decisions